ORIGINAL ARTICLE |
|
Year : 2015 | Volume
: 63
| Issue : 4 | Page : 318-322 |
|
Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy
Pradeep Venkatesh1, Varun Gogia1, Shikha Gupta1, Akshay Tayade1, Neha Shilpy1, Bhavin M Shah1, Randeep Guleria2
1 Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India 2 Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Dr. Varun Gogia Retina and Uvea Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/0301-4738.158070
|
|
Purpose: To evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC). Methods: Patients with acute macular SC with lesions threatening and/or involving fovea were enrolled. All patients received CyP (1 g/m 2 ) for 3 days followed by high-dose oral steroids (1.5 mg/kg) tapered over 6 months and monitored for visual acuity, response to treatment and systemic side effects. Results: Eight patients (seven unilateral and one bilateral) with median age of 27 years (range: 13-40 years) were recruited. Mean visual acuity at presentation was 0.71 ± 0.35 logarithm of the minimum angle of resolution while postpulse visual acuity was 0.40 ± 0.32. Final mean visual acuity at 1-year was 0.31 ± 0.23 (P ≤ 0.05). Three eyes had recurrence and 3 patients developed transient hair loss with no other adverse effect. Conclusion: Intravenous CyP provides rapid resolution of lesion activity and thereby helps in maintaining good functional acuity. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|